Study: NCT03272347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Islatravir
Description: Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Doravirine
Description: Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Lamivudine
Description: Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Description: Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Description: Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Description: Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Description: Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doravirine/Islatravir
Description: Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/Islatravir
Description: Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/Islatravir
Description: Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/Islatravir
Description: Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks